Imaging in gastrointestinal stromal tumours: current status and future directions
Received 5 January 2010; received in revised form 27 January 2010; accepted 3 February 2010. published online 28 April 2010.
Gastrointestinal stromal tumours (GISTs) have distinct biological and treatment-related features posing challenges for imaging. In this review the importance of imaging in different stages of patient management is discussed, emphasizing the unique characteristics of GISTs. Potential pitfalls of using the standard response criteria on conventional imaging have been highlighted. These include size measurements, which may not adequately reflect response rates, pseudo-progression, and spurious new lesions. Furthermore, the role of positron emission tomography/computed tomography (PET/CT) in early response evaluation and in the detection of both primary and acquired resistance is explored. The current role and future directions of use of both conventional and metabolic imaging in the management of GISTs are discussed.
aDepartment of Radiology, The Christie NHS Foundation Trust, Manchester, UK
bDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
Guarantor and correspondent: Department of Radiology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Tel.: +44 161 4463053; fax: +44 161 4463827.